SUZHOU ZELGEN BIOPHARMACEUTICALS CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.3 CNY | -0.14% |
|
+0.36% | +4.46% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 15,526 | 14,112 | 10,008 | 14,014 | 14,638 | - | - |
| Enterprise Value (EV) 1 | 15,526 | 14,112 | 10,008 | 14,014 | 14,638 | 14,638 | 14,638 |
| P/E ratio | -47.6 x | -31.3 x | -21.6 x | -48.6 x | -213 x | 114 x | 46.9 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 561 x | 74.1 x | - | 36.3 x | 19.5 x | 10.9 x | 6.71 x |
| EV / Revenue | 561 x | 74.1 x | - | 36.3 x | 19.5 x | 10.9 x | 6.71 x |
| EV / EBITDA | -57.6 x | -34.1 x | - | -56.2 x | -472 x | 80.4 x | 26 x |
| EV / FCF | -38.7 x | -26.9 x | - | -47.4 x | -63 x | -40.3 x | -64.3 x |
| FCF Yield | -2.59% | -3.72% | - | -2.11% | -1.59% | -2.48% | -1.56% |
| Price to Book | 9.6 x | 11.5 x | - | 8.58 x | 9.96 x | 9.34 x | 7.22 x |
| Nbr of stocks (in thousands) | 2,40,000 | 2,40,000 | 2,40,000 | 2,64,708 | 2,64,708 | - | - |
| Reference price 2 | 64.69 | 58.80 | 41.70 | 52.94 | 55.30 | 55.30 | 55.30 |
| Announcement Date | 25/02/21 | 23/02/22 | 27/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 27.66 | 190.4 | - | 386.4 | 749.8 | 1,349 | 2,181 |
| EBITDA 1 | -269.7 | -414.2 | - | -249.5 | -31 | 182 | 563.6 |
| EBIT 1 | -304.8 | -459 | - | -297.8 | -70 | 149.5 | 534.4 |
| Operating Margin | -1,102.02% | -241.14% | - | -77.06% | -9.34% | 11.08% | 24.5% |
| Earnings before Tax (EBT) 1 | -304.8 | -465.1 | - | -299.1 | -73 | 148 | 351.4 |
| Net income 1 | -319.2 | -451 | -462 | -278.6 | -68 | 128.5 | 312.2 |
| Net margin | -1,154.08% | -236.92% | - | -72.09% | -9.07% | 9.52% | 14.31% |
| EPS 2 | -1.360 | -1.880 | -1.930 | -1.090 | -0.2600 | 0.4850 | 1.180 |
| Free Cash Flow 1 | -401.5 | -525.4 | - | -295.3 | -232.4 | -363.6 | -227.8 |
| FCF margin | -1,451.64% | -275.98% | - | -76.43% | -31% | -26.95% | -10.44% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 25/02/21 | 23/02/22 | 27/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -402 | -525 | - | -295 | -232 | -364 | -228 |
| ROE (net income / shareholders' equity) | -19.9% | -29.1% | - | -20% | -11.4% | 6.02% | 22% |
| ROA (Net income/ Total Assets) | -27.9% | -22.2% | - | -12.2% | -5.3% | 4.3% | 14.8% |
| Assets 1 | 1,145 | 2,030 | - | 2,278 | 1,283 | 2,988 | 2,116 |
| Book Value Per Share 2 | 6.740 | 5.130 | - | 6.170 | 5.550 | 5.920 | 7.660 |
| Cash Flow per Share 2 | -1.430 | -1.890 | - | -0.8800 | -0.9200 | - | 1.810 |
| Capex 1 | 57.7 | 70.7 | - | 62.6 | 21.1 | 316 | 461 |
| Capex / Sales | 208.53% | 37.16% | - | 16.2% | 2.81% | 23.43% | 21.14% |
| Announcement Date | 25/02/21 | 23/02/22 | 27/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
55.3
CNY
Average target price
64
CNY
Spread / Average Target
+15.73%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +4.46% | 2.03B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- 688266 Stock
- Financials Suzhou Zelgen Biopharmaceuticals Co.,Ltd.
